ALB and type 2 diabetes mellitus: A phase II study in T2D patients with albuminuria demonstrated that emapticap pegol (NOX-E36), another antagonist of MCP-1, was safe and well tolerated during administration, and significantly improved urinary albumin/creatinine ratio (ACR) compared to the placebo group (96).